Evidence map›Paper›PMID 37533255›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2023

STING/ACSL4 axis-dependent ferroptosis and inflammation promote hypertension-associated chronic kidney disease.

Li Gao, Junsheng Zhang, Tingting Yang, Ling Jiang, Xueqi Liu, Sheng Wang, Xian Wang, Yuebo Huang, Huaying Wang, Mengya Zhang and 6 more

Open access · greenAbstract read
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed, 1 pooled it
19.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

80 citing papers in PubMed, 1 synthesis or guideline pooled it, 116 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Ferroptosis in kidney disease.Nature reviews. Nephrology · 2026
    Review
  7. Ferroptosis as a target mechanism in heart and kidney disease.The Journal of clinical investigation · 2026
    Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

20 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Li GaoDepartment of Nephropathy, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, China; Center for Scientific Research of Anhui Medical University, Hefei 230022, China.
Junsheng ZhangThe First Affiliated Hospital of Anhui Medical University, Hefei 230032, China; Anhui Public Health Clinical Center, Hefei 230032, China.
Tingting YangState Key Laboratory of Natural Medicines, Department of Pharmacology, China Pharmaceutical University, Nanjing 211198, China.
Ling JiangDepartment of Nephropathy, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.
Xueqi LiuDepartment of Nephropathy, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.
Sheng WangCenter for Scientific Research of Anhui Medical University, Hefei 230022, China.
Xian WangDepartment of Nephropathy, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.
Yuebo HuangDepartment of Nephropathy, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.
Huaying WangDepartment of Nephropathy, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.
Mengya ZhangDepartment of Nephropathy, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.
Tingting GongThe First Affiliated Hospital of Anhui Medical University, Hefei 230032, China.
Lijuan MaDepartment of Nephropathy, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.
Chao LiInflammation and Immune-Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei 230032, China.
Chaoyong HeState Key Laboratory of Natural Medicines, Department of Pharmacology, China Pharmaceutical University, Nanjing 211198, China. Electronic address: chaoyonghe@cpu.edu.cn.
Xiao-Ming MengInflammation and Immune-Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei 230032, China. Electronic address: mengxiaoming@ahmu.edu.cn.
Yonggui WuDepartment of Nephropathy, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, China; Center for Scientific Research of Anhui Medical University, Hefei 230022, China. Electronic address: wuyonggui@medmail.com.cn.
Anhui Medical University · CNChina Pharmaceutical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypertension is a primary modifiable risk factor for cardiovascular diseases, which often induces renal end-organ damage and complicates chronic kidney disease (CKD). In the present study, histological analysis of human kidney samples revealed that hypertension induced mtDNA leakage and promoted the expression of stimulator of interferon genes (STING) in renal epithelial cells. We used angiotensin II (AngII)- and 2K1C-treated mouse kidneys to elucidate the underlying mechanisms. Abnormal renal mtDNA packing caused by AngII promoted STING-dependent production of inflammatory cytokines, macrophage infiltration, and a fibrogenic response. STING knockout significantly decreased nuclear factor-κB activation and immune cell infiltration, attenuating tubule atrophy and extracellular matrix accumulation in vivo and in vitro. These effects delayed CKD progression. Immunoprecipitation assays and liquid chromatography-tandem mass spectrometry showed that STING and ACSL4 were directly combined at the D53 and K412 amino acids of ACSL4. Furthermore, STING induced renal inflammatory response and fibrosis through ACSL4-dependent ferroptosis. Last, inhibition of ACSL4 using small interfering RNA, rosiglitazone, or Fer-1 downregulated AngII-induced mtDNA-STING-dependent renal inflammation. These results suggest that targeting the STING/ACSL4 axis might represent a potential strategy for treating hypertension-associated CKD.

Indexed as

FerroptosisHypertensionInflammationMembrane ProteinsRenal Insufficiency, ChronicAngiotensin IIAnimalsDisease Models, AnimalDNA, MitochondrialHumansMaleMiceMice, KnockoutSignal TransductionSTING ProteinAngiotensin IIDNA, MitochondrialMembrane ProteinsSTING1 protein, humanSting1 protein, mouseSTING Proteinangiotensin IIchronic kidney diseasehypertensioninflammationrenal end-organ damagestimulator of interferon genes

Identifiers

PMID37533255
PMCPMC10556226
OpenAlexW4385483781

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.